{"id":1108,"date":"2020-08-26T09:33:00","date_gmt":"2020-08-26T09:33:00","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/two-cardiac-markers-for-high-risk-of-heart-failure-and-death\/"},"modified":"2021-01-08T11:09:39","modified_gmt":"2021-01-08T11:09:39","slug":"two-cardiac-markers-for-high-risk-of-heart-failure-and-death","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/two-cardiac-markers-for-high-risk-of-heart-failure-and-death\/","title":{"rendered":"Two cardiac markers for high risk of heart failure and death"},"content":{"rendered":"

New research suggests that GlycA, a newly identified blood marker, and C-reactive protein both independently predict major adverse cardiac events, including heart failure and death. Patients who have high levels of both biomarkers are at especially high risk.<\/span>
\n <\/span>
\nThat\u2019s the finding of researchers from the Intermountain Medical Center Heart Institute in Salt Lake City, who teamed with LipoScience Laboratories to examine the markers to see if the two proteins, each previously linked to inflammation, are independent or related and whether either or both can identify patients at elevated risk for cardiovascular events.<\/span>
\n <\/span>
\nThe research grew out of an earlier analysis that paired plasma samples collected as part of the Intermountain Heart Collaborative Study with an assay developed by LipoScience that uses nuclear magnetic resonance technology to measure, among other things, the particle numbers in low-density lipoprotein (LDL) cholesterol, often called \u201cbad\u201d cholesterol. While scanning the plasma samples with the nuclear magnetic resonance technology, LipoScience had detected the GlycA and determined it to be a novel marker of inflammation.<\/span>
\n <\/span>
\nEarly research by the Intermountain Medical Center Heart Institute team showed that GlycA can predict heart attack risk; inflammation makes it more likely cholesterol plaques will rupture.<\/span>
\n <\/span>
\nGlycA didn\u2019t predict coronary artery disease nearly as well, said Brent Muhlestein, MD, co-director of cardiology research at Intermountain Medical Center and the study\u2019s lead author.<\/span>
\n <\/span>
\nC-reactive protein has already been shown to accurately predict adverse heart events and coronary artery disease, so the researchers wondered if the two are independent of each other, or if GLycA just offers another way to measure the effects of CRP.<\/span>
\n <\/span>
\nUsing the same plasma samples \u2014 part of more than 30,000 DNA samples collected over the course of 25 years by the Intermountain Medical Center Heart Institute\u2014 the researchers compared the value of both GlycA and CRP in predicting future heart attacks, strokes, or death.<\/span>
\n <\/span>
\nFor the study, nearly 3,000 patients undergoing coronary angiography were followed, two-thirds of them male. Sixty-five percent of them had been diagnosed with coronary artery disease, 42 percent with acute coronary syndrome, and 26 percent with diabetes.<\/span>
\n <\/span>
\n\u201cThe correlation between GlycA and CRP was only modest,\u201d said Dr. Muhlestein. \u201cSome patients had a high level of one and a low level of the other and vice versa. But the two proteins independently predicted future risk, and if you had both, it was the worst scenario completely. It tells us that GlycA is perhaps something important.\u201d<\/span>
\n <\/span>
\nHow important will be the focus for future research. Dr. Muhlestein said his research team would like to identify exactly what GlycA is, what it does, and the underlying physiology of its connection to inflammation.<\/p>\n

<\/span>
\nIntermountain Medical Center Heart Institute<\/span>
\nintermountainhealthcare.org\/news\/2017\/03\/people-who-have-high-levels-of-two-cardiac-markers-at-high-risk-of-heart-failure-and-death\/<\/link><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

New research suggests that GlycA, a newly identified blood marker, and C-reactive protein both independently predict major adverse cardiac events, including heart failure and death. Patients who have high levels of both biomarkers are at especially high risk.   That\u2019s the finding of researchers from the Intermountain Medical Center Heart Institute in Salt Lake City, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1108"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=1108"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1108\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=1108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=1108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=1108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}